<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Collee J</submitter><funding>FNRS</funding><pagination>e080353</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11227760</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>14(7)</volume><pubmed_abstract>&lt;h4>Introduction&lt;/h4>Pregnancies resulting from in vitro fertilisation are associated with an increased risk of developing hypertensive disorders of pregnancy, such as preeclampsia, when compared with naturally conceived pregnancies.&lt;h4>Objective&lt;/h4>The efficacy of aspirin prophylaxis to reduce the incidence of preeclampsia is well established in naturally conceived pregnancies identified as high risk for developing preeclampsia. However, the efficacy of aspirin to reduce the rate of preeclampsia for all pregnancies resulting from in vitro fertilisation remains uncertain, although in vitro fertilisation conception is a well-known risk factor for preeclampsia. Therefore, the purpose of this scoping review is to provide a comprehensive overview of the current literature regarding the use of</pubmed_abstract><journal>BMJ open</journal><pubmed_title>Low-dose aspirin prophylaxis to prevent hypertensive disorders of pregnancy after in vitro fertilisation: a scoping review protocol.</pubmed_title><pmcid>PMC11227760</pmcid><funding_grant_id>40017857</funding_grant_id><pubmed_authors>Vervier J</pubmed_authors><pubmed_authors>Noel L</pubmed_authors><pubmed_authors>Chantraine F</pubmed_authors><pubmed_authors>Vandenput S</pubmed_authors><pubmed_authors>Collee J</pubmed_authors><pubmed_authors>Henry L</pubmed_authors><pubmed_authors>Nisolle M</pubmed_authors></additional><is_claimable>false</is_claimable><name>Low-dose aspirin prophylaxis to prevent hypertensive disorders of pregnancy after in vitro fertilisation: a scoping review protocol.</name><description>&lt;h4>Introduction&lt;/h4>Pregnancies resulting from in vitro fertilisation are associated with an increased risk of developing hypertensive disorders of pregnancy, such as preeclampsia, when compared with naturally conceived pregnancies.&lt;h4>Objective&lt;/h4>The efficacy of aspirin prophylaxis to reduce the incidence of preeclampsia is well established in naturally conceived pregnancies identified as high risk for developing preeclampsia. However, the efficacy of aspirin to reduce the rate of preeclampsia for all pregnancies resulting from in vitro fertilisation remains uncertain, although in vitro fertilisation conception is a well-known risk factor for preeclampsia. Therefore, the purpose of this scoping review is to provide a comprehensive overview of the current literature regarding the use of</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Jul</publication><modification>2025-04-26T05:39:59.467Z</modification><creation>2025-04-06T11:36:06.924Z</creation></dates><accession>S-EPMC11227760</accession><cross_references><pubmed>38964795</pubmed><doi>10.1136/bmjopen-2023-080353</doi></cross_references></HashMap>